KalVista's Sebetralstat Shows Promise in Pediatric HAE Trial

Event summary

  • KalVista presented interim Phase 3 data from the KONFIDENT-KID trial at the 2026 Global Angioedema Leadership Conference, showing positive results for sebetralstat in treating HAE attacks in children aged 2-11.
  • The trial, the largest pediatric HAE study ever, used a proprietary oral disintegrating tablet formulation, with median time to symptom relief of 1.5 hours and complete resolution in 12 hours.
  • No serious or treatment-related adverse events were reported, and the trial completed enrollment a year ahead of schedule.
  • KalVista plans to file a new drug application in the US in Q3 2026, with a potential launch in 2027.

The big picture

KalVista's positive interim data for sebetralstat in pediatric HAE patients addresses a critical unmet need, as current treatments rely on injectable or intravenous administration. The trial's success could redefine the treatment paradigm for HAE in children, potentially reducing the burden on patients and caregivers. The strategic shift towards oral on-demand therapies aligns with broader industry trends favoring patient-friendly drug formulations.

What we're watching

Regulatory Approval
Whether the FDA will approve sebetralstat for pediatric use based on the interim trial data, potentially making it the first oral on-demand therapy for this age group.
Market Adoption
The pace at which sebetralstat could gain market share if approved, given the current lack of oral on-demand treatments for pediatric HAE patients.
Competitive Dynamics
How KalVista's success could pressure competitors to develop more pediatric-friendly HAE treatments, reshaping the treatment landscape.